Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Short Interest Down 55.5% in August

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totaling 5,662 shares, a drop of 55.5% from the August 15th total of 12,737 shares. Based on an average daily trading volume, of 19,110 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.1% of the shares of the stock are sold short.

Institutional Investors Weigh In On Cryo-Cell International

An institutional investor recently raised its stake in Cryo-Cell International stock. Susquehanna International Group LLP increased its position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) by 40.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,064 shares of the company’s stock after buying an additional 4,046 shares during the period. Susquehanna International Group LLP owned about 0.17% of Cryo-Cell International worth $45,000 as of its most recent SEC filing. 10.44% of the stock is owned by institutional investors and hedge funds.

Cryo-Cell International Stock Down 0.5%

Shares of Cryo-Cell International stock traded down $0.02 on Tuesday, hitting $4.38. The company’s stock had a trading volume of 15,038 shares, compared to its average volume of 16,797. The company has a market capitalization of $35.30 million, a P/E ratio of -14.60 and a beta of 0.47. Cryo-Cell International has a 52-week low of $2.72 and a 52-week high of $5.01. The firm has a fifty day moving average price of $3.81 and a 200-day moving average price of $3.58.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share for the quarter. The business had revenue of $7.78 million for the quarter.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.